News
FDA Approves Obe-cel, a Novel CD19 CAR T Product for ALL
- Author:
- Sharon Worcester, MA
Obe-cel has been shown to improve response rates and survival, particularly in adult patients with low leukemia burden.
News
Cannabis in Cancer: What Oncologists and Patients Should Know
- Author:
- Sharon Worcester, MA
Access to and use of cannabis alongside cancer care have outpaced the science on evidence-based indications, according to an ASCO expert panel.
News
Gotistobart Trial for NSCLC on Partial Clinical Hold
- Author:
- Sharon Worcester, MA
The trial assessed the safety and efficacy of the agent vs docetaxel as monotherapy in patients with metastatic NSCLC that progressed despite...
News
ACS: Breast Cancer Incidence Rising, Mortality Disparities Persist
- Author:
- Sharon Worcester, MA
Deaths from breast cancer, however, declined from 1989 to 2022, with an overall drop of 44%.
News
Isatuximab Quadruplet Approval Could Change the Landscape for Treating Myeloma
- Author:
- Sharon Worcester, MA
Findings of phase 3 IMROZ trial demonstrated the efficacy of Isa-VRd, a four-drug combo, in treating patients newly diagnosed with myeloma.
News
MM: First CAR T-Cell Therapy to Exhibit OS Benefit
- Author:
- Sharon Worcester, MA
CARTITUDE-4 study update indicated that CAR T-cell therapy improves overall survival in relapsed/refractory multiple myeloma.
News
FDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLC
- Author:
- Sharon Worcester, MA
The drug was approved for patients whose disease has not progressed during or after concurrent or sequential platinum-based chemoradiation therapy...
News
AACR Cancer Progress Report: Big Strides and Big Gaps
- Author:
- Sharon Worcester, MA
The report focused on strides made in cancer care, prevention, and early detection and highlighted areas where more research and attention are...
News
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications
- Author:
- Sharon Worcester, MA
The drug combo was the first programmed death–ligand 1 inhibitor to gain approval for subcutaneous administration.
News
Debate: Should CAR T Best Be Used in Early MM Relapse?
- Author:
- Sharon Worcester, MA
When patients with myeloma relapse, blood cancer specialists disagree on whether and when to treat them with CAR T-cell therapy.
News
To Choose the Best First-line Drug for CML, Consider Efficacy and Cost
- Author:
- Sharon Worcester, MA
For treatment value, imatinib remains the CML gold standard: a generic, second-generation TKI that helps improve treatment-free remission rates....
News
Jeffrey Weber, MD, PhD, Giant of Cancer Care, Dies
- Author:
- Sharon Worcester, MA
He was a principal investigator on many studies, including pivotal clinical drug trials in melanoma.
News
FDA Approves Axatilimab for Chronic GVHD
- Author:
- Sharon Worcester, MA
For children and adults with graft versus host disease, a first-in-class monoclonal antibody axatilimab has received FDA approval.
News
FDA Approves First Targeted Therapy for Gliomas With IDH Mutations
- Author:
- Sharon Worcester, MA
The approval of vorasidenib marks “one of the biggest advances in low-grade glioma in more than two decades.”
News
FDA Expands Dostarlimab-gxly Approval for Endometrial Cancer
- Author:
- Sharon Worcester, MA
‘This is the only immuno-oncology treatment regimen that has shown a statistically significant overall survival benefit for the full patient...